We are live on ! Find out more
MLYS icon

Mineralys Therapeutics
MLYS

77 hedge funds and large institutions have $252M invested in Mineralys Therapeutics in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 28 increasing their positions, 11 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

155% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 11

69% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 13

13% more funds holding

Funds holding: 68 → 77 (+9)

3.24% more ownership

Funds ownership: 61.64% → 64.89% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

41% less capital invested

Capital invested by funds: $429M → $252M (-$177M)

Holders
77
Holders Change
+9
Holders Change %
+13.24%
% of All Funds
1.22%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
22
Increased
28
Reduced
11
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
B
Braidwell
Connecticut
+$19.2M
2
CA
CHI Advisors
New York
+$7.41M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$5.97M
4
Millennium Management
Millennium Management
New York
+$4.75M
5
LCM
Laurion Capital Management
New York
+$3.78M

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$14.3M
2
APM
Avidity Partners Management
Texas
-$13.1M
3
GPP
Great Point Partners
Connecticut
-$9.31M
4
Jennison Associates
Jennison Associates
New York
-$6.06M
5
ASP
Adams Street Partners
Illinois
-$1.53M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$43M – – –
RCM
2
RA Capital Management
Massachusetts
$30.2M – – –
ASP
3
Adams Street Partners
Illinois
$21.9M -$1.53M -117,172 -5%
B
4
Braidwell
Connecticut
$19.2M +$19.2M +1,473,600 +268%
SOCM
5
SR One Capital Management
Pennsylvania
$17.1M – – –
Fidelity Investments
6
Fidelity Investments
Massachusetts
$11.3M +$5.97M +457,815 +63%
RSCM
7
Rock Springs Capital Management
Maryland
$11.1M – – –
LCM
8
Laurion Capital Management
New York
$9.22M +$3.78M +289,847 +43%
Vanguard Group
9
Vanguard Group
Pennsylvania
$8.92M +$152K +11,629 +1%
RI
10
RTW Investments
New York
$8.77M – – –
BlackRock
11
BlackRock
New York
$8.51M +$141K +10,789 +1%
SAM
12
Sectoral Asset Management
Quebec, Canada
$8M +$2.95M +226,046 +37%
Janus Henderson Group
13
Janus Henderson Group
United Kingdom
$6.34M +$3.36M +257,755 +63%
CA
14
CHI Advisors
New York
$5.41M +$7.41M +568,379 New
DCM
15
Driehaus Capital Management
Illinois
$4.77M +$18.1K +1,391 +0.3%
SFM
16
Sphera Funds Management
Israel
$4.33M +$652K +50,000 +12%
Franklin Resources
17
Franklin Resources
California
$4.28M +$222 +17 +0%
American Century Companies
18
American Century Companies
Missouri
$3.99M +$2.18K +167 +0%
Millennium Management
19
Millennium Management
New York
$3.46M +$4.75M +364,343 New
Geode Capital Management
20
Geode Capital Management
Massachusetts
$2.85M +$173K +13,304 +5%
State Street
21
State Street
Massachusetts
$2.19M +$245K +18,780 +9%
SSA
22
Schonfeld Strategic Advisors
New York
$1.83M +$981K +75,248 +64%
WP
23
Woodline Partners
California
$1.66M – – –
Point72 Asset Management
24
Point72 Asset Management
Connecticut
$1.55M +$1.62M +124,185 +318%
ECM
25
ExodusPoint Capital Management
New York
$1.52M -$444K -34,084 -18%
1
2 3 4

MLYS Hedge Fund Activity: Q3 2023 in Review

77 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Mineralys Therapeutics (MLYS) for Q3 2023, worth a combined $252M — down 41% from $429M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new MLYS positions and 13 closed out — a net gain of 9 holders — while 28 added to existing stakes and 11 trimmed.

The largest buyer was Braidwell, adding an estimated $19.2M. The largest seller was Deerfield Management, exiting entirely with an estimated $14.3M sold.

  • 77 institutional investors held Mineralys Therapeutics (MLYS) as of Q3 2023, up from 68 in Q2 2023.
  • Funds reported $252M of Mineralys Therapeutics stock for Q3 2023, down 41% quarter-over-quarter.
  • 22 funds opened new Mineralys Therapeutics positions in Q3 2023 and 13 closed out, a net change of +9 holders.
  • The largest Mineralys Therapeutics buyer in Q3 2023 was Braidwell, an estimated $19.2M added.
  • The largest Mineralys Therapeutics seller in Q3 2023 was Deerfield Management, an estimated $14.3M sold.

Based on aggregated 13F filings for Q3 2023.